№ files_lp_4_process_1_36627
File format: docx Character count: 50462 File size: 4738 KB
Year: 2026
Region / City: USA, Irvine, CA
Document Type: Research Study
Institution: Chapman University, University of California
Author: Rudy Chang, Devaraj V. Chandrashekar, G. Chuli Roules, Nataraj Jagadeesan, Emi Iwasaki, Adenike Oyegbesan, Hayk Davtyan, Rachita K. Sumbria
Target Audience: Researchers, Pharmacologists, Neurologists
Period of Validity: Ongoing, Preclinical phase
Approval Date: 2026
Modification Date: Not Applicable
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
S_Table 1 The Active Ingredients of GXNT and Their Pharmacokinetic Parameters
Document type: Supplementary table
Title as given: S_Table 1 The active ingredients of GXNT and their pharmacokinetic parameters
Subject: Active ingredients of GXNT and pharmacokinetic parameters
Herb names: SB; LD
Parameters included: Mol ID; Molecule Name; OB (%); DL
Abbreviations defined: OB, Oral bioavailability; DL, Drug-likeness
Note: * No relevant target was found for this compound
Number of listed compounds: 70+
Language of content: English
Scientific field: Pharmacology; Phytochemistry
Format: Tabular dataset
RNA THERAPEUTICS: CLINICAL PHARMACOKINETIC AND THERAPEUTIC MONITORING
Year: 2023
Region / City: Nashik, Maharashtra, India
Topic: RNA therapeutics, clinical pharmacokinetics, RNA-based therapies
Document Type: Review article
Organization: Krantiveer Vasantrao Narayanrao Naik Shikshan Prasarak Sanstha, Institute of Pharmaceutical Education & Research
Author: Sakshi L. Bodke, Mayuri N. Jagtap, Avinash B. Darekar
Target Audience: Researchers, clinicians, pharmaceutical industry professionals
Period of Validity: Ongoing
Date of Approval: 2023
Date of Changes: None
Keywords: RNA therapeutics, clinical pharmacokinetics, pharmacodynamics, absorption
Note: Contextual Description
Supplementary Materials for a Comprehensive Review on the Chemical Properties, Plant Sources, Pharmacological Activities, Pharmacokinetic and Toxicological Characteristics of Tetrahydropalmatine
Year: 2021
Region / City: China and Southeast Asia
Subject: Pharmacology, Ethnobotany, Phytochemistry
Document Type: Supplementary material / Scientific review data
Institution: Chengdu University of Traditional Chinese Medicine
Authors: Qinyun Du, Xianli Meng, Shaohui Wang
Target Audience: Researchers and professionals in pharmacology and traditional medicine
Data Coverage: Plant species, pharmacological activities, extraction methods, and chemical properties
Date of Publication: 2021
References Included: Yes, multiple sources cited for plant species and pharmacological effects
Language: English
Document Structure: Tables with plant sources, pharmacological actions, and extraction methods
Supplementary Table Legends for Pharmacokinetic and Metabolic Analyses of Vemurafenib
Type of document: Supplementary table legends
Research field: Pharmacology
Research topic: Metabolism and pharmacokinetics of vemurafenib
Analyzed compound: Vemurafenib
Metabolite: OH-vemurafenib
Biological system: Human liver microsomes (HLM) and transgenic mouse models
Experimental models: Cyp3aKO/Cyp3a13+/+, huCYP3A4/3A7, huPXR/huCAR/huCYP3A4/3A7, huPXR/huCAR mice
Inducers and treatments: PCN, RIF, PB, elacridar
Analytical methods: Hill equation modeling, Michaelis–Menten kinetics, Spearman’s rank correlation
Measured parameters: Apparent kinetic parameters and pharmacokinetic (PK) parameters
Related figures: Figure 2, Figure 3, Figure 4, Figure 5
Dose described: Vemurafenib 100 mg/kg
Statistical notes: Comparisons between vehicle and treatment groups with significance indicators
Supplemental Digital Content: Pharmacokinetic and Pharmacodynamic Analyses of Meropenem in Pediatric Patients with Sepsis
Year: 2018
Country: United States
Subject: Pharmacokinetics and pharmacodynamics of meropenem in pediatric sepsis
Document Type: Supplemental scientific tables and figures
Drug: Meropenem
Pathogen Focus: Pseudomonas aeruginosa
Data Source: SENTRY Antimicrobial Surveillance Program
Study Population: Children younger than 17 years
Clinical Condition: Sepsis
Parameters Analyzed: Observed volume of distribution (Vz_obs), observed clearance (Cl_obs), minimum inhibitory concentration (MIC), pharmacodynamic target attainment (T>MIC), estimated glomerular filtration rate (eGFR), fluid balance
Dosage Regimens Evaluated: 20 mg/kg, 40 mg/kg, 60 mg/kg
Evaluation Period: Day 1 to Day 3 after start of meropenem infusion
Geographic Scope of Isolate Data: United States medical centers
Topics: brain-penetrating erythropoietin Pharmacokinetic